Report Overview

The EU Lymphoma Drugs market size stood at USD 1.8 billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period

The Lymphoma market in the EU has a possible future opportunity for market expansion coupled with untapped potential. According to the statistics, lymphomas are the second most frequent subtype of nodal lymphoid malignancies in the EU. The annual incidence in the EU is 23 new cases/100 000. The annual incidence of this disease is rare but has subsequently increased over time. Major pharmaceutical companies functioning in the oncology field are focusing on progressive strategic plans such as acquisitions & mergers with other companies to consolidate their foothold in the EU lymphoma market



Market Growth Drivers

The rise in the incidence of lymphoma is expected to drive the growth of the lymphoma drug market. The government has amplified their funding in R&D for the development of lymphoma treating drugs which would further augment the growth market during the forecast period. Advances in therapeutical approaches and the continuous innovation of therapies are among other factors driving growth